Leuprorelin Acetate is a synthetic gonadotropin-releasing hormone (GnRH) agonist used across oncology, gynecology, and pediatric endocrinology. Indications are classified below by strength of evidence.

Established / Approved Uses

Advanced prostate cancer — palliative treatment to reduce testosterone to castrate levels, alone or in combination with radiation therapy or an anti-androgen.
Endometriosis — management of pelvic pain and associated symptoms, typically for a limited duration (up to 6 months), with or without "add-back" hormone therapy.
Uterine fibroids (leiomyomata) — short-term use (generally with concomitant iron therapy) to reduce fibroid size and correct anemia before surgery.
Central precocious puberty (CPP) — suppression of pubertal hormone secretion in children who meet diagnostic criteria, under pediatric endocrinology supervision.

Adjunct / Combination Uses

Used together with an anti-androgen during the first weeks of prostate cancer treatment to blunt the initial testosterone "flare."
Used with norethindrone acetate "add-back" therapy in endometriosis to reduce bone mineral density loss during extended courses.

Off-Label / Guideline-Supported Uses

Pituitary down-regulation in assisted reproductive technology (ART) / controlled ovarian stimulation protocols.
Ovarian suppression for fertility preservation during chemotherapy, and in selected premenopausal breast cancer treatment protocols.
Puberty suppression in adolescents with gender dysphoria (specialist-supervised, off-label).

Dosage & Administration of Leuprorelin Acetate

Dosing of Leuprorelin Acetate is individualized by indication, formulation, and dosing interval. It must be administered by a healthcare professional as a subcutaneous or intramuscular depot injection.

Indication	Typical Adult/Pediatric Dose
Advanced prostate cancer	7.5 mg IM/SC monthly; or 22.5 mg every 3 months; or 30 mg every 4 months; or 45 mg every 6 months (depot formulations), continued long-term as directed by the treating oncologist.
Endometriosis	3.75 mg IM monthly for up to 6 months, or 11.25 mg every 3 months; add-back therapy may be used to extend duration.
Uterine fibroids	3.75 mg IM monthly, generally for up to 3 months preoperatively, with concomitant iron supplementation.
Central precocious puberty	Weight-based initial dose (e.g., approximately 0.3 mg/kg, minimum 7.5 mg) IM monthly, titrated to hormonal suppression; or an age/weight-appropriate depot formulation given every 1, 3, 4, or 6 months, under pediatric endocrinology supervision.

See Reconstitution for preparation of depot suspension formulations. See Precautions and Warnings for management of the initial flare reaction.

Side Effects of Leuprorelin Acetate

Common side effects of Leuprorelin Acetate relate to the induced hypogonadal state and include:

Hot flashes/flushes and sweating
Injection site reactions (pain, redness, induration)
Headache and mood changes
Decreased libido and, in men, erectile dysfunction, gynecomastia
In women, vaginal dryness and initial spotting/vaginal bleeding
Bone mineral density reduction with prolonged use
Transient worsening of prostate cancer symptoms (bone pain, urinary symptoms) or endometriosis symptoms during the initial "flare" — see Precautions and Warnings

Contraindications of Leuprorelin Acetate

Leuprorelin Acetate is contraindicated in:

Known hypersensitivity to Leuprorelin Acetate, other GnRH agonists, or any component of the formulation.
Pregnancy, when Leuprorelin Acetate is used for gynecologic indications (endometriosis, uterine fibroids) or pediatric indications — fetal harm may occur.
Undiagnosed abnormal vaginal bleeding.

Frequently Asked Questions about Leuprorelin Acetate

What is Leuprorelin Acetate used for?

Leuprorelin Acetate is a GnRH agonist used to treat advanced prostate cancer, endometriosis, uterine fibroids, and central precocious puberty in children, by suppressing sex hormone production.

Will I notice a flare of symptoms when I start Leuprorelin Acetate?

Yes, a temporary rise in testosterone or estrogen can occur in the first 1–2 weeks of Leuprorelin Acetate therapy, which may briefly worsen bone pain or urinary symptoms in prostate cancer, or endometriosis symptoms; your doctor may prescribe a short course of another medicine to reduce this effect.

Can Leuprorelin Acetate be used during pregnancy?

No. Leuprorelin Acetate is contraindicated in pregnancy for endometriosis, fibroid, and pediatric indications because it may cause fetal harm; pregnancy should be ruled out before starting treatment and effective non-hormonal contraception used during therapy.

How is Leuprorelin Acetate given?

Leuprorelin Acetate is given as a subcutaneous or intramuscular depot injection by a healthcare professional, at intervals of 1, 3, 4, or 6 months depending on the product and dose prescribed.

What are the common side effects of Leuprorelin Acetate?

Common effects include hot flashes, injection site reactions, headache, decreased libido, mood changes, and gradual bone density loss with prolonged use.

How long will I need to take Leuprorelin Acetate?

Duration depends on the condition being treated — often long-term for prostate cancer, but generally limited to a few months for endometriosis or uterine fibroids due to bone density concerns; your doctor will determine the appropriate duration for you.

Disclaimer

The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.

Leuprorelin Acetate: Brands, Price & Uses in Bangladesh

Lucrin Depot3.75 mg

Lucrin Depot11.25 mg

About Leuprorelin Acetate

Indications of Leuprorelin Acetate